RLAY Relay Therapeutics

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 6, 2024.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit or .

Contact:

Megan Goulart

617-545-5526

Media:

Dan Budwick

1AB

973-271-6085



EN
30/10/2024

Underlying

RLAYRelay Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Relay Therapeutics

Jonathan Moreland
  • Jonathan Moreland
Free Trial
RLAY Relay Therapeut...
ABOS Acumen Pharmace... ... (+6)

InsiderInsights.com Daily Ratings Report: January 23, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

RLAY RELAY THERAPEUTICS
ABOS ACUMEN PHARMACEUTICALS
PEO INC.
MXF PETROLEUM & RESOURCES CORPORATION
THE MEXICO FUND
INC.
01/24/25 January 24, 2025 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Co...

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 7:30 a.m. PT. The presentation will be webcast live and may be accessed through Relay Therapeutics’ website under...

January 7, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
TTSH Tile Shop Holdi...
MHI Pioneer Municip... ... (+10)

InsiderInsights.com Daily Ratings Report: January 6, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TTSH TILE SHOP HOLDINGS INC.
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ETON ETON PHARMACEUTICALS
RLAY RELAY THERAPEUTICS
BIGZ BLACKROCK INNOVATION AND GROWTH TST
BUKS BUTLER NATIONAL CORP
GLSI GREENWICH LIFESCIENCES INC
MEGI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
MIO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
EVM EATON VANCE INSD CALIF MUN BD FD
01/07/25 January 7, 2025 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulve...

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations at RP2D Data support planned initiation of 2L pivotal study in 2025 Next-generation triplet combination with atirmociclib (CDK4-selective) initiated & ribociclib triplet combination ongoing Relay Therapeutics to host a conference ...

December 11, 2024 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+...

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium Company to host conference call on Wednesday, December 11, 2024 at 7am ET CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that updated clinical data for RLY-2608 600mg BID + fulvestrant in patients with PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast...

December 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch